UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(Mark One)

[X]      QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE
         ACT OF 1934
                  For the quarterly period ended June 30, 2003

[ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
      For the transition period from _________________ to _________________

                        Commission file number 333-83152


                                   Inyx, Inc.
        (Exact name of small business issuer as specified in its charter)

           Nevada                                                75-28700720
(State or other jurisdiction of                                (IRS Employer
 incorporation or organization)                              Identification No.)


                  801 Brickell, 9th Floor, Miami, Florida 33131
                    (Address of principal executive offices)

                                 (305) 789-6649
                          (Issuer's telephone number)

         Check whether the issuer (1) filed all reports  required to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements  for the past 90 days:
Yes [X] No [_].

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

         Check whether the registrant  filed all documents and reports  required
to be  filed  by  Section  l2,  13 or  15(d)  of  the  Exchange  Act  after  the
distribution of securities under a plan confirmed by a court. Yes [ ] No [ ]


<PAGE>

APPLICABLE ONLY TO CORPORATE ISSUERS

         State the number of shares  outstanding of each of the issuer's classes
of common equity, as of July 31, 2003: 24,950,000 shares of common stock.

Transitional Small Business Disclosure Format (Check one):  Yes [ ] No [X]

Include whether Registrant is an accelerated filer:    Yes [ ] No [X]































                                       2
<PAGE>
<TABLE>
<CAPTION>

                         PART I-- FINANCIAL INFORMATION
                          Item 1. Financial Statements.
                        INYX, INC. (f/k/a Doblique, Inc.)
                      Condensed Consolidated Balance Sheets
                                 (In Thousands)

                                                               June 30,       December 31,
                                                                 2003             2002
                                                              (Unaudited)
<S>                                                          <C>              <C>
                                     Assets
Current assets:
         Cash                                                $          31    $          25
         Accounts receivables, net                                   3,127             --
         Inventory                                                     845             --
         Other current assets                                        1,391             --
                                                             -------------    -------------
                           Total current assets                      5,394               25
                                                             -------------    -------------

Property, plant and equipment, net                                   5,152             --
Livestock, net                                                        --                 59
Goodwill                                                            10,665             --
                                                             -------------    -------------
                                                                    15,817               59
                                                             -------------    -------------

                                                             $      21,211    $          84
                                                             =============    =============


                      Liabilities and Stockholders' Equity

Current liabilities:
         Line of credit with financial institution           $       2,294    $        --
         Accounts payable                                            1,896                8
         Other current liabilities                                     385              223
         Current portion of long term debt                           1,386             --
                                                             -------------    -------------
                  Total current liabilities                          5,961              231
                                                             -------------    -------------

Term loan                                                            1,879             --
Convertible note                                                     4,201             --
                                                             -------------    -------------
                  Total long term liabilities                        6,080             --
                                                             -------------    -------------
Stockholders' equity (deficit):
               Preferred Stock - $0.001 par value
                10,000,000 shares authorized
                 -0-  shares issued and outstanding                   --               --
         Common stock - $0.001 par value
          150,000,000 shares authorized
           24,950,000 shares issued and
           outstanding                                                  25                1
         Additional paid-in capital                                 10,817               48
         Accumulated equity                                         (1,692)            (196)
              Foreign currency translation adjustment                   20             --
                                                             -------------    -------------
                  Total stockholders' equity (deficit)               9,170             (147)
                                                             -------------    -------------
Total liabilities and stockholders' equity                   $      21,211    $          84
                                                             =============    =============
</TABLE>


See accompanying notes to financial statements.




                                       3
<PAGE>
<TABLE>
<CAPTION>

                        INYX, INC. (f/k/a Doblique, Inc.)
                 Condensed Consolidated Statements of Operations
                    (In Thousands, Except per Share Amounts)

                                                     Six months ended June 30,      Three months ended June 30,
                                                           (unaudited)                     (unaudited)
                                                           -----------                     -----------

                                                        2003            2002            2003            2002
                                                    ------------    ------------    ------------    ------------
<S>                                                 <C>             <C>             <C>             <C>

Net Revenues                                        $      5,068    $       --      $      5,068    $       --
Cost of goods sold                                         3,933            --             3,933            --
                                                    ------------    ------------    ------------    ------------

         Gross profit                                      1,135            --             1,135            --

Expenses:
         General and administrative expenses               2,510            --             2,511            --
         Selling expenses                                     96            --                96            --
                                                    ------------    ------------    ------------    ------------

                  Total operating expenses                 2,606            --             2,607            --

(Loss) from operations before other expenses              (1,471)           --            (1,472)           --
Other income (expense):
         Interest expense                                    159            --               159            --
         Depreciation and amortization                       128            --               128            --
                                                    ------------    ------------    ------------    ------------

                                                             287            --               287            --

Loss before provision for income taxes and
             Discontinued operations                      (1,758)           --            (1,759)           --

Provision for income taxes                                   288            --               288            --
                                                    ------------    ------------    ------------    ------------

Loss from continuing operations                           (1,470)           --            (1,471)           --

Loss from discontinued operations, net of tax                (25)            (50)           --               (28)
                                                    ------------    ------------    ------------    ------------
Net loss                                            $     (1,495)   $        (50)   $     (1,471)   $        (28)
                                                    ============    ============    ============    ============
Loss per share of common stock outstanding
         Basic and fully diluted
                  -From continuing operations       $      (0.12)   $      (0.00)   $      (0.08)   $      (0.00)
                                                    ============    ============    ============    ============
                  - After discontinued operations   $      (0.12)   $      (0.01)   $      (0.08)   $      (0.01)
                                                    ============    ============    ============    ============
Weighted-average number of shares
  outstanding - basic and fully diluted               12,150,829       5,000,000      19,223,077       5,000,000
                                                    ============    ============    ============    ============
</TABLE>


See accompanying notes to financial statements.


                                       4
<PAGE>
<TABLE>

                        INYX, INC. (F/K/A DOBLIQUE, INC.)

  Statements of Changes in Stockholders' Equity and Other Comprehensive Income


                                                                                         Other
                                     Common Stock                     Additional       Compreha-
                                       Number of                       Paid-in           nsive        Accumulated
                                        Shares        Par Value        Capital        Income/Loss       Deficit          Total
                                     ------------    ------------    ------------    ------------    ------------    ------------
<S>                                  <C>             <C>             <C>             <C>             <C>             <C>
Balances at
  December 31, 2000                     1,000,000    $      1,000            --                      $       (983)   $         17

Capital contributed by a
   controlling Stockholder in the
   form of executive compensation            --              --            24,000                            --            24,000

Net loss                                     --              --              --                           (82,144)        (82,144)
                                     ------------    ------------    ------------    ------------    ------------    ------------

Balances at
  December 31, 2001                     1,000,000           1,000          24,000            --           (83,127)        (58,127)

Capital contributed by a
   controlling Stockholder in the
   form of executive compensation            --              --            24,000                            --            24,000

Net loss                                     --              --              --                          (113,066)       (113,066)
                                     ------------    ------------    ------------    ------------    ------------    ------------

Balances at
  December 31, 2002                     1,000,000           1,000          48,000            --          (196,193)       (147,193)

Stock split (March 3, 2003)             4,000,000           4,000          (4,000)                                           --

Capital contributed by a
   controlling Stockholder in the
   form of executive compensation                                               6                                               6

Capital contributed by a
   controlling Stockholder in the
   form of debt forgiveness                                               170,000                                         170,000

Net loss                                                                                                  (25,000)        (25,000)
                                     ------------    ------------    ------------    ------------    ------------    ------------

Balance at March 31, 2003               5,000,000           5,000         214,006            --          (221,193)         (2,187)

Issuance of Stock for finders fees      2,450,000           2,450       1,302,175                                       1,304,625

Issuance of Stock for services          1,500,000           1,500         797,250                                         798,750

Issuance of Stock for reverse
   acquisition of Inyx Pharma          16,000,000          16,000       8,504,000                                       8,520,000

Net loss                                                                                               (1,470,560)     (1,470,560)

Foreign currency translation
  Adjustment                               20,000          20,000
                                     ------------    ------------    ------------    ------------    ------------    ------------

Balance at June 30, 2003               24,950,000    $     24,950    $ 10,817,431    $     20,000    $ (1,691,753)   $  9,170,628
                                     ============    ============    ============    ============    ============    ============
</TABLE>

See accompanying notes to financial statements.



                                       5
<PAGE>
<TABLE>
<CAPTION>

                        INYX, INC. (f/k/a Doblique, Inc.)
                      Consolidated Statements of Cash Flows
                                 (In Thousands)

                                                         Six months ended June 30,    Three months ended June 30,
                                                               (unaudited)                    (unaudited)
                                                               -----------                    -----------

                                                             2003           2002           2003           2002
                                                         -----------    -----------    -----------    -----------
 <S>                                                      <C>            <C>            <C>            <C>
Cash flows from operating activities:
         Loss for the period                             $    (1,470)   $      --      $    (1,471)   $      --
         Adjustments to reconcile net loss to net cash
         provided by operating activities:
         Depreciation                                            128           --              128
         Deferred income taxes                                  (299)          --             (299)          --
         Issuance of stock for services                          799           --              799           --
         Change in non-cash operating working capital         (2,828)          --           (2,826)          --
                                                         -----------    -----------    -----------    -----------

         Net cash used in continuing
         operating activities                                 (3,670)          --           (3,669)          --
                                                         -----------    -----------    -----------    -----------
         Cash (used in) provided from discontinued
         operations                                               35             (9)          --               15
                                                         -----------    -----------    -----------    -----------
                                                              (3,635)            (9)        (3,669)            15


Cash flows from investing activities:
         Purchase of fixed assets                             (5,280)          --           (5,280)          --
         Goodwill and acquisition costs                         (841)          --             (841)          --
                                                         -----------    -----------    -----------    -----------

Net cash (used in) provided by investing activities           (6,121)          --           (6,121)          --
                                                         -----------    -----------    -----------    -----------

Cash flows from financing activities:
         Advances by stockholder                                  50           --              109           --
         Advances against line of credit                       2,294           --            2,294           --
         Proceeds from issuance of long term debt              3,593           --            3,593           --
         Repayment of long term debt                            (328)          --             (328)          --
         Proceeds from issuance of promissory note             4,133           --            4,133           --
                                                         -----------    -----------    -----------    -----------

Net cash provided by financing activities                      9,742           --            9,801           --
                                                         -----------    -----------    -----------    -----------

Effect of foreign exchange rate changes on cash                   20           --               20           --
                                                         -----------    -----------    -----------    -----------

Net increase (decrease) in cash                                    6             (9)            31             15
Cash at beginning of period                                       25             28           --                4
                                                         -----------    -----------    -----------    -----------

Cash at end of period                                    $        31    $        19    $        31    $        19
                                                         ===========    ===========    ===========    ===========
</TABLE>





                                       6
<PAGE>



                          NOTES TO FINANCIAL STATEMENTS


NOTE 1:  Unaudited Consolidated Financial Statements
------   -------------------------------------------

         The accompanying  consolidated financial statements of the Company have
been prepared in accordance with the instructions to Form 10QSB and,  therefore,
omit or condense certain  footnotes and other  information  normally included in
financial  statements  prepared in accordance with generally accepted accounting
principles.   It  is  suggested  that  these  consolidated  condensed  financial
statements should be read in conjunction with the Company's financial statements
and notes thereto included in the Company's audited financial statements on Form
10-KSB for the fiscal year ended December 31, 2002.

         The accounting  policies followed for interim  financial  reporting are
the same as those  disclosed  in Note 1 of the  Notes  to  Financial  Statements
included in the Company's audited financial statements for the fiscal year ended
December 31, 2002, which are included in Form 10-KSB.

         In the opinion of  management,  the  unaudited  consolidated  financial
statements include all necessary  adjustments  (consisting of normal,  recurring
accruals)  for a  fair  presentation  of  the  financial  position,  results  of
operations  and  cash  flow  for  the  interim  periods   presented.   Preparing
consolidated  financial  statements  requires  management to make  estimates and
assumptions  that affect the reported amounts of assets,  liabilities,  revenues
and expenses.  Actual results may differ from these  estimates.  Interim results
are not  necessarily  indicative  of  results  for a full year.  The  results of
operations for the  three-month  period ended June 30, 2003 are not  necessarily
indicative  of  operating  results  to  be  expected  for  a  full  year.  These
consolidated financial statements of Inyx, Inc. and its wholly-owned subsidiary:
Inyx Pharma  Limited.  All  intercompany  transactions  and  balances  have been
eliminated in consolidation.

NOTE 2:  Comprehensive Income
------   --------------------

         Comprehensive   income   (loss)  from  foreign   currency   translation
adjustments  for the six months ended June 30, 2003 was  $20,000.  There were no
such adjustments in the prior year.

NOTE 3:  Shareholders' Equity (Deficit)
------   ------------------------------

         On April 17, 2003 the Company  issued  2,450,000  shares of  restricted
common stock as a fee to Saintsbury  Management Corp.,  Grosvenor Trust Company,
Ltd., Liberty Management LLC,  TriFinity Venture  Corporation,  and BPL Corp. as
finders fees for their role in facilitating the transaction with Inyx Pharma. On
April 21, 2003 the Company issued 1,500,000 shares of restricted common stock to
Mr. Jordan Slatt as consideration for business advisory and financial consulting
services.  On June 26, 2003, the Company filed an S-8 registration  statement to
register the Slatt securities.

         On April 28, 2003 the Company  issued  16,000,000  shares of restricted
common stock for 100% of the issued and  outstanding  shares of Inyx Pharma in a
reverse merger acquisition.



                                       7
<PAGE>

NOTE 4:  Stock Based Compensation
------   ------------------------

         On May 1, 2003 the Company  adopted a Stock Option Plan which  provides
for the granting of incentive  stock options and non qualified stock options for
the benefit of employees officers and directors. The total number of shares that
may be issued under the plan amounts to 5,000,000.  The exercise price per share
must be at least  equal  to the fair  market  price  at the time of  grant.  The
Company Granted  2,755,000  options during the three month period ended June 30,
2003.

         The Company  applies the  intrinsic  value based  method of  Accounting
Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees,
and  related  interpretations  in  accounting  for its  stock  option  plan.  No
stock-based  employee  compensation  cost is  reflected  in net  income,  as all
options  granted under the plan had an exercise  price equal to the market value
of the underlying common stock on the date of grant. The Company's pro forma net
income (loss) and earnings  (loss) per share would have been as indicated  below
had the fair value of all option  grants been  charged to salaries,  wages,  and
benefits  in  accordance   with  SFAS  No.  123,   Accounting  for   Stock-Based
Compensation (in thousands, except per share data):
<TABLE>
<CAPTION>

                                    Six Months Ended June 30,    Three Months Ended June 30,
                                        2003           2002           2003           2002
(in thousands)                      -----------    -----------    -----------    -----------
<S>                                 <C>            <C>            <C>            <C>

Reported net loss                   $    (1,495)   $      --      $    (1,471)   $      --
Less:
Stock based employee compensation
(net of tax) using the fair value
method                                      747           --            373             --
                                    --------------------------------------------------------

Pro forma net loss                  $    (2,242)   $      --      $    (1,844)   $      --
                                    --------------------------------------------------------


Reported net loss per share         $     (0.12)   $     (0.00)   $     (0.08)    $    (0.00)
                                    --------------------------------------------------------

Pro Forma net loss per share        $     (0.18)   $     (0.01)   $     (0.96)    $    (0.01)
</TABLE>

These pro forma amounts may not be  representative  of future  disclosures since
the  estimated  fair value of stock  options is  amortized to expense over their
vesting period. Additional options may be granted in the future.

NOTE 5:  Earnings (loss) per share
------   -------------------------

         Basic earnings per share ("EPS") is computed using the weighted average
number of common shares outstanding  during the period.  Diluted EPS is computed
using the weighted average number of common and dilutive potential common shares
outstanding  during the period.  Dilutive  potential  common  shares  consist of
common stock  issuable upon  exercise of stock options using the treasury  stock
method.  No  adjustments  to  earnings  were  made  for  purposes  of per  share
calculations.  The  Company  has  reported a net loss for both the three and six
month  periods ended June 30, 2003 and 2002.  As a result,  3,055,000  shares of
common stock  issuable  upon  exercise of stock  options and warrants  have been
excluded from the  calculation  of diluted loss per share for both the three and



                                       8
<PAGE>

six  month  periods  ended  June  30,  2003  because  their  inclusion  would be
antidilutive.  At June 30,  2003,  outstanding  options and  warrants to acquire
3,055,000 shares of common stock were not considered potentially dilutive common
shares due to the  exercise  price being higher than the stock price used in the
EPS calculation.

NOTE 6:  Warrants
------   --------

         The Company granted  300,000  warrants to purchase a maximum of 300,000
whole  shares of common  stock of the  Company at prices  ranging  from $1.10 to
$3.10 per share, during the three month period ended June 30, 2003. The warrants
expire on September 26, 2006.

NOTE 7: Acquisitions
------  ------------

         On April 28, 2003, the Company acquired 100% of the outstanding  common
stock of Inyx Pharma Limited ("Inyx Pharma") by issuing 16,000,000 shares of the
Company's  common  stock.  Total cost of  acquisition  included  $1.6 million of
additional  indirect  costs of which  $334 was paid in cash and the  balance  by
issuing stock as  consideration  for finders fees. Inyx Pharma Limited is in the
business of  manufacturing  pharmaceutical  aerosol sprays along with irrigation
and injectible  solutions.  The transaction resulted in recording of goodwill in
the amount of $8.71  million,  which the Company  will assess on an annual basis
for impairment.

         On March 7, 2003, Inyx Pharma,  the Company's  fully owned  subsidiary,
acquired the business assets of Miza UK from the court appointed  Administrator,
the transaction was recorded as a purchase and resulted in recording of goodwill
amounting to $1.95  million.  Additionally,  Inyx Pharma  issued $7.5 million in
debt to effect the transaction.

NOTE 8:  Discontinued Operations
------   -----------------------

         Effective  March 6, 2003 the Company sold assets to the  operations  of
Doblique,  Inc., to a third party for cash and has  discontinued the business of
owning  and  racing  thoroughbred  race  horses.  Accordingly,  the  results  of
operations  and  changes  in  cash  flow of the  business  have  been  disclosed
separately from those of continuing operations.

NOTE 9:  Subsequent Event
------   ----------------

         On July 1,  2003  the  Company  entered  into a two year  Business  and
Corporate  Development  Advisory Consulting Services Agreement (the "Agreement")
with a  consultant  to  provide  advice  and  council  regarding  the  Company's
strategic   business  and  development   plans  and  other   consulting   needs.
Consideration for this Agreement amounts to approximately  $170,000 over the two
year term.




                                       9
<PAGE>
<TABLE>
<CAPTION>

PRO FORMA FINANCIAL STATEMENT INFORMATION

         The  following is a condensed  consolidated  balance  sheet showing the
fair values of assets acquired and liabilities assumed as of March 31, 2003:


         INYX, INC. (f/k/a Doblique, Inc.)
    Unaudited Pro Forma Condensed Consolidated Balance Sheet
March 31, 2003
     (In Thousands)

                                                         Inyx, Inc.       Pro          Inyx         Pro          Total
                                                                         Forma        Pharma        Forma
                                                                          Adj.                       Adj.
                                                                          (1)                        (2)
                                                         ----------    ----------   ----------   ----------    ----------
<S>                                                      <C>           <C>          <C>          <C>           <C>
Current assets
      Cash                                               $        0                 $      433                        433
      Inventory                                               1,318                      1,318
      Prepaid and other assets                                  677                        677
                                                         ----------                 ----------                 ----------
            Total current assets                               --                        2,428                      2,428

Property, plant and equipment, net                                                       5,131                      5,131
Goodwill                                                                                 1,916   $    8,716        10,632
Investment in subsidiary                                               $   10,159                   (10,159)            0
                                                         ----------                 ----------                 ----------
            Total assets                                 $     --                   $    9,475                 $   18,191
                                                         ==========                 ==========                 ==========


Liabilities and Stockholders' Equity
Current liabilities
      Revolving loan                                                                $       53                 $       53
      Accounts payable and accrued expenses              $        2                        476                        478
      Due to shareholder                                                      334                                     334
                                                         ----------                 ----------                 ----------
            Total current liabilities                             2                        529                        865

Term loan                                                                                3,494                      3,494
Promissory note                                                                          4,009                      4,009
                                                         ----------                 ----------                 ----------
            Total liabilities                                     2                      8,032                      8,368
                                                         ----------                 ----------                 ----------

Stockholders' Equity
      Common stock                                                5            18            2           (2)           23
      Subscription receivable                                                             (641)         641          --
      Additional paid in capital                                214         9,807        2,082       (2,082)       10,021
      Accumulated equity                                       (221)                                                 (221)
                                                         ----------                 ----------                 ----------
            Total stockholders' equity                           (2)                     1,443                      9,823
                                                         ----------                 ----------                 ----------

            Total liabilities and stockholders' equity   $        0                 $    9,475                 $   18,191
                                                         ==========                 ==========                 ==========
</TABLE>


(1) To record the acquisition of all of the issued and outstanding  common stock
of Inyx Pharma in a stock for stock  reverse  merger  requiring  the issuance of
16,000,000 of the Company's common stock
(2) To  eliminate  subsidiary  equity  and to record  goodwill  relating  to the
acquisition of the issued and outstanding common stock of Inyx Pharma




                                       10
<PAGE>

         The following condensed consolidated  statements of operations is based
on the assumption  that the  acquisition of Inyx Pharma Limited took place as of
January 1, 2003 and includes the operations of Miza Pharmaceuticals (UK) Limited
("Miza UK") the  predecessor  to Inyx Pharma  Limited for the period  January 1,
2003 to March 7, 2003 and Inyx Pharma  Limited  for the period  March 7, 2003 to
June 30, 2003.  On March 7, 2003,  Inyx Pharma  Limited  acquired the  operating
assets  of Miza  UK  from a court  appointed  Administrator  and  continued  the
operations of Miza in unbroken  succession.  The acquisition did not include the
operations  of Miza's Bio Pharma  division  which have been  eliminated  for the
purposes of these pro forma statements.

         For the  periods  ended  June  30,  2002 and  December  31,  2002,  the
operations of Miza UK as  predecessor  to Inyx Pharma  Limited are presented for
comparative analysis after the elimination of Miza's biopharma division.

         For the periods  ended June 30, 2003 and 2002 and  December  31,  2002,
operations relating to the business of the former Doblique,  Inc. now Inyx, Inc.
have been  eliminated  from these pro forma  statements as if the divestiture of
assets and liabilities and the discontinuance of related operations  occurred on
January 1, 2003 and 2002.

























                                       11
<PAGE>
<TABLE>
<CAPTION>

                        INYX, INC. (f/k/a Doblique, Inc.)
      Unaudited Pro Forma Condensed Consolidating Statements of Operations
                  For the Six Month Period Ended June 30, 2003
                                 (In Thousands)

                                                                                         Pro Forma
                                                                                            Adj.
                                               Inyx, Inc.    Inyx Pharma   Miza UK (1)      (2)           Total
                                               ----------    ----------    ----------                  ----------
<S>                                            <C>           <C>           <C>           <C>           <C>
Net Revenues                                   $     --      $    5,068    $    2,396                  $    7,464
Cost of goods sold                                   --           3,933         1,876                       5,809
                                               ----------    ----------    ----------                  ----------
     Gross profit                              $     --      $    1,135    $      520                        1,655

Expenses:
    Livestock and Jockey expenses                       2                                        (2)         --
    General and administrative expenses             1,425         1,094           535            (9)        3,045
    Selling expenses                                                96             51                         147
                                               ----------    ----------    ----------                  ----------

          Total operating expenses             $    1,427    $    1,190    $      586                       3,192
                                               ----------    ----------    ----------                  ----------

(Loss) from operations before other expenses       (1,427)          (55)          (66)                     (1,537)

Other expense (income):
    Administration expense                                                         55           (55)         --
    Loss on sale of livestock                          11                                       (11)         --
    Management fees                                  (619)          619          --                          --
    Interest expense                                                159           429                         588
    Depreciation and amortization                       3           128           348            (3)          476
                                               ----------    ----------    ----------                  ----------
                                                     (605)          906           832                       1,064

Loss before provision for income taxes               (822)         (961)         (898)                     (2,600)

Provision for income taxes                                          288           269                          557
                                               ----------    ----------    ----------                   ----------

Net (loss)                                     $     (822)   $     (673)   $     (629)                     $(2,043)
                                               ==========    ==========    ==========                   ==========
</TABLE>


(1) Excluding the activity of Bio Pharma  division which was not included in the
acquisition
(2) This is the  adjustment to remove the results of operations  relating to the
business  of owning and  racing  horses.  The  Company  divested  itself of this
business on March 6, 2003.



                                       12
<PAGE>
<TABLE>
<CAPTION>

                        Inyx, Inc. (f/k/a Doblique, Inc.)
      Unaudited Pro Forma Condensed Consolidating Statements of Operations
                  For the Six Month Period Ended June 30, 2002
                                 (In Thousands)


                                                                                              Pro Forma
                                                                                                 Adj.        Consolidated
                                                                 Inyx, Inc.     Miza UK (1)      (2)             Total

<S>                                                              <C>            <C>           <C>             <C>
Net Revenues                                                     $        34    $    14,012            (34)   $    14,012
Cost of goods sold                                                      --           10,034                        10,034
                                                                 -----------    -----------                   -----------
                          Gross profit                                    34          3,978                         3,978

Expenses:
              Livestock and Jockey expenses                               46           --              (46)          --
              General and administrative expenses                         16          2,471            (16)         2,471
              Selling expenses                                          --              203                           203
                                                                 -----------    -----------                   -----------

                                      Total operating expenses            62          2,674                         2,674
                                                                 -----------    -----------                   -----------

(Loss) Income from operations before other expenses                      (28)         1,304                         1,303

Other expense:
              Loss on sale of livestock                                   12           --              (12)          --
              Management fees                                           (326)          --                            (326)
              Interest expense                                          --              848                           848
              Depreciation and amortization                               10            432            (10)           432
                                                                 -----------    -----------                   -----------
                                                                        (304)         1,280                           954

 Profit before provision for income taxes                                276             24                           350

Provision for income taxes                                              --             (105)                         (105)
                                                                 -----------    -----------                   -----------

Net income (loss)                                                $       276    $       (81)                  $       245
                                                                 ===========    ===========                   ===========
</TABLE>


(1) Excluding  the activity  relating to the Bio Pharma  division  which was not
included in the acquisition.
(2) This is the  adjustment to remove the results of operations  relating to the
business of owning and racing thoroughbred race horses. The horses were sold for
cash to a third party on March 6, 2003.


Item 2. Management's Discussion and Analysis or Plan of Operations

         The financial  information set forth in the following discussion should
be read in  conjunction  with,  and  qualified in its entirety by, the financial
statements of the Company included elsewhere herein.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

         This quarterly report contains certain  forward-looking  statements and
information relating to the Company that are based on the beliefs of the Company
or management as well as assumptions made by and information currently available
to  the  Company  or  management.   When  used  in  this  document,   the  words
"anticipate,"   "believe,"   "estimate,"   "expect"  and  "intend"  and  similar
expressions,  as they relate to the Company or its  management,  are intended to
identify forward-looking statements. Such statements reflect the current view of


                                       13
<PAGE>

the  Company   regarding  future  events  and  are  subject  to  certain  risks,
uncertainties  and  assumptions,  including the risks and  uncertainties  noted.
Should  one or more of  these  risks or  uncertainties  materialize,  or  should
underlying assumptions prove incorrect,  actual results may vary materially from
those  described  herein  as  anticipated,   believed,  estimated,  expected  or
intended. In each instance,  forward-looking information should be considered in
light of the accompanying meaningful cautionary statements herein.

OVERVIEW

         The Company,  was incorporated  under the laws of Nevada in March 2000.
In  July  2002,  it  became  a  publicly-traded  company  when  it  completed  a
registration statement for the sale, by its principal stockholder,  of 2,450,000
shares of common  stock.  The  Company's  common stock is traded on the Nasdaq's
Over-the-Counter Bulletin Board ("OTCBB"). The Company voluntarily files annual,
quarterly  and periodic  reports  with the  Securities  and Exchange  Commission
pursuant to Section 15(d) of the Securities Exchange Act of 1934.

         On February 19th,  2003, the Company issued a press release  announcing
that the Company's Board of Directors had approved a 5 for 1 forward stock split
of the Company's  common stock in the form of a dividend of four million  shares
of common stock.  The record date for the forward  split was March 3, 2003.  The
Company had been in the business of owning and racing  thoroughbred  race horses
at various major horse racing tracks  throughout the United  States.  The horses
previously  owned by the Company  were sold for cash on March 6, 2003 to a third
party.

         On March 24, 2003, the Company's  controlling  stockholder  accepted an
unsolicited offer to sell a controlling block, 2,250,000 shares of common stock,
representing approximately 45% of the Company's issued and outstanding shares to
Medira Investments LLC. As part of that transaction,  the Company's  controlling
stockholder  also  provided a release and  discharge of all  liabilities  to the
Company. At that time, the Company's  controlling  stockholder was owed $125,959
by Company.

         On March 26,  2003,  Doblique  issued a press  release  announcing  the
change of control  transaction  and that the  Company  would now pursue  further
strategic   investment   opportunities   in  a  number  of  sectors  within  the
pharmaceutical,    biotechnology   and   medical   devices   industries.   These
opportunities   would   include   research   and   development,   manufacturing,
distribution, and intellectual property acquisitions.

         On April 22, 2003, the Company  announced that it had agreed to acquire
all of the issued and outstanding securities of Inyx Pharma Limited, a specialty
pharmaceutical  company  incorporated under the laws of England and Wales ("Inyx
Pharma"). Pursuant to that announcement,  on April 17, 2003, the Company entered
into an  Agreement  with  five  parties  in which  the  Company  agreed to issue
2,450,000 of shares of  restricted  common  stock as a fee to these  parties for
their role in facilitating the transaction with Inyx Pharma.

         On April 21, 2003,  the Company  also entered into a two year  Business
Advisory and  Financial  Consulting  Services  Agreement  with a  consultant  to
provide advice and counsel regarding the Company's  strategic business plans. As
consideration for this Consulting Agreement, the Company issued 1,500,000 shares
of restricted  securities to the Consultant.  The Company  subsequently filed an
S-8 registration statement to register those securities on June 26, 2003.


                                       14
<PAGE>

         On April 28,  2003,  the  Company  concluded  its  acquisition  of Inyx
Pharma.  The  transaction  consisted  of an exchange of 100% of the  outstanding
common stock of Inyx Pharma, for 16 million shares of restricted common stock of
the  Company  (the  "Exchange"),  representing  approximately  64% of the shares
outstanding after the exchange, as a result of which Inyx Pharma became a wholly
owned  subsidiary  of  the  Company.   Inyx  Pharma  focuses  its  expertise  on
development-led  manufacturing  in the sterile  pharmaceutical,  finished-dosage
form,  outsourcing sector. It specializes in niche products and technologies for
the treatment of respiratory,  allergy, dermatological,  and topical conditions.
Inyx  Pharma's  client base is  comprised of  blue-chip  ethical  pharmaceutical
companies, branded generic firms and biotechnology groups.

         On May 1, 2003 the Company  adopted a Stock  Option Plan that  provides
for the granting of incentive  stock options and non qualified stock options for
the benefit of employees officers and directors. The total number of shares that
may be issued under the plan amounts to 5,000,000.  The exercise price per share
must be at least equal to the fair market price at the time of grant.

         To reflect its new operating business,  the Company changed its name on
May 6, 2003 to Inyx, Inc.

         On June 26, 2003,  the Company filed an S-8  registration  statement to
register its Stock Option Plan.

RESULTS OF OPERATIONS

Three-Month and Six-Month Periods Ended June 30, 2003

         The following discussion of the Company's results of operations for the
three and six month periods ended June 30, 2003 focuses on the operations of its
wholly  owned  subsidiary,  Inyx  Pharma,  which was acquired on April 28, 2003.
Prior to the  acquisition  of Inyx Pharma,  the Company  divested  itself of all
prior  operations  conducted as Doblique,  Inc. The timing and  reporting of the
acquisition  is such  that the  substance  of the  discussion  centering  on the
Company's basic financial  statements refers primarily to the three months ended
June 30, 2003.

         As  a  consequence,  a  more  extensive  comparative  analysis  of  the
Company's operations for the three and six month periods ended June 30, 2003 and
2002 can be found in those  sections of this  discussion  dealing with pro forma
financial statement information.

         Net Revenue

         Net revenues for the  three-months  and six-months  ended June 30, 2003
were $5.1  million,  an increase of 100% from the  comparative  periods in prior
year.  The  increase  in revenue  was  attributed  solely to the newly  acquired
business  of Inyx  Pharma.  For the three and six month  periods  ended June 30,
2003, the Company's top three customers accounted for approximately $2.8 million
or 54% of the Company's total net revenues.



                                       15
<PAGE>

         Pro forma net  revenues  for the six month  period  ended June 30, 2003
were $7.5 million as compared to $14 million for the six month period ended June
30, 2002. Revenues decreased by $6.5 million or 46% as compared to the pro forma
revenue in the comparable period in 2002. The decrease is attributed to the fact
that Inyx Pharma's predecessor company, Miza Pharmaceuticals (UK) Limited ("Miza
UK"), was acquired out of Administration. Although most of the customer base was
retained,  the  level  of  revenues  has not yet  been  restored  to the  levels
experienced by the predecessor company prior to the Administration  period. This
is primarily due to the Administration  process,  where necessary  materials and
components were not purchased to meet customer  demand.  The top three customers
accounted  for $3.8  million or 51% of pro forma net revenues for the six months
period  ended June 30, 2003 as compared  to $10.3  million,  from the same three
customers, or 67% of total pro forma net revenue for the six months period ended
June 30, 2002.

         The  Company  expects  revenues  from   manufacturing  and  development
revenues to be restored to levels experienced by the business assets acquired by
Inyx Pharma prior to the Administration period.

         The Company's  revenues are derived from  pharmaceutical  manufacturing
and product formulation and development outsourcing services,  including product
stability,  commercial  scale-up,  and validation and regulatory support for its
clients'  products.  Future  contract  revenues are dependant upon the Company's
clients  maintaining  or  obtaining  regulatory  approval  for the sale of their
products in their designated markets.  The Company does not presently derive any
revenues from the sale of its own products.

         Cost of Goods Sold

         Cost of goods sold is associated  with  manufacturing  and  development
revenues and includes materials, labor, factory overheads and technical affairs,
which includes quality control and quality assurance regulatory support amounted
to $3.9  million or 78% of net  revenues  ($5.1  million)  for the three and six
month periods ended June 30, 2003.

         Pro forma  cost of goods sold for the six month  period  ended June 30,
2003 amounted to $5.8 million or 78% of net revenues  ($7.5 million in pro forma
net revenues) as compared to pro forma costs of goods sold of $10 million or 71%
of net  revenues  ($14.0  million in pro forma net  revenues)  for the six month
period ended June 30,  2002.  The increase in cost of goods sold as a percentage
of  revenues  is  mostly  due to a change  in  product  mix and phase out of the
Chlorofluorocarbon  ("CFC") based respiratory  product line. In 2003 the Metered
Dose  Inhaler  ("MDI")  line  accounted  for only 15% of overall  production  as
compared  to 41% in the same period in 2002.  Historically  CFC  production  has
lower  material  costs as compared to the non CFC  products.  The Company is now
focused on phasing in non CFC respiratory products

         The  Company  expects  the cost of goods sold to be  restored to levels
experienced  by the  business  assets  acquired  by  Inyx  Pharma  prior  to the
Administration period as more customer contracts are initiated or renewed.

         Gross Profit

         Gross  Profit  amounted to $1.1  million or 22% of net  revenues  ($5.1
million) for the three and six month periods ended June 30, 2003.



                                       16
<PAGE>

         Pro forma  gross  profit for the six month  period  ended June 30, 2003
amounted to $1.7 million or 22% of net revenues  ($7.5  million in pro forma net
revenues)  as  compared  to pro forma  gross  profit of $4 million or 28% of net
revenues  ($ 14  million)  for the six month  period  ended June 30,  2002.  The
decrease in the pro forma gross  profit for the six month  period ended June 30,
2003 is a result of the Miza UK business  operation being in  Administration  in
the first two months of the year,  the phase out of the CFC products,  and start
up costs relating to integration of the newly acquired business.

         The Company  expects gross profit to be restored to levels  experienced
by the  business  assets  acquired  by Inyx Pharma  prior to the  Administration
period as more customer  contracts  are  initiated or renewed,  and raw material
inventory levels are restored.

         General and Administrative Expenses

         General and  administrative  expenses which includes corporate overhead
costs were  $2.5million  or 50% of net revenues ($5.1 million) for the three and
six month periods ended June 30, 2003.

         Pro forma general and administrative expenses were $3 million or 41% of
pro forma net revenues  ($7.5  million) for the six month periods ended June 30,
2003 as  compared  to pro forma  general  and  administrative  expenses  of $2.4
million or 17% of net revenues ($14 million) for the six month period ended June
30, 2002.

         The increase in general and  administrative  expenses for the pro forma
period ended June 30, 2003 is  primarily  due to the number of  significant  one
time non  recurring  costs  which were  incurred  by the  Company in its reverse
acquisition of Inyx Pharma,  including start up and integration costs. These one
time  non-recurring  costs amounted to  approximately  $1.1 million and included
business  consulting  fees of $800 thousand,  accounting and legal costs of $125
thousand and corporate development costs of $175 thousand.

         In  addition  during  the six  month  period  ended  June 30,  2003 pay
adjustment  for key employees  amounted to  approximately  $112  thousand.  Also
product  liability  and property  insurance  premiums  were  approximately  $120
thousand  higher in the six month  period ended June 30, 2003 as compared to the
same period in prior year.

         Additionally,  during the pro forma period ended June 30, 2003, Miza UK
incurred  a number of  additional  general  and  administrative  costs  directly
attributable to the Administration and sale processes the company was undergoing
at the time.

         Selling Expenses

         Selling  expenses were $96 thousand or 2% of net revenues for the three
and six month periods ended June 30, 2003.

         Pro forma  selling  expenses  amounted  to $147  thousand  or 2% of net
revenues  ($7.5  million)  and  $203  thousand  or 1.5% of net  revenues  ($14.0
million) for the six month  periods  ended June 30, 2003 and 2002  respectively.
Selling expense consists primarily of salaries,  commissions and marketing costs
associated  with the  commercial  department of the business.  Pro forma selling
expenses as a percentage of revenues  have slightly  increased due to increasing
marketing efforts following acquisition of the Inyx Pharma business.



                                       17
<PAGE>

         Operating Loss/Income

         Loss from  operations  amounted to $1.5  million or 29% of net revenues
for the three and six month periods ended June 30, 2003.

         Pro forma loss from operations for the six months period ended June 30,
2003 amounted to $1.5 million or 20% of pro forma net revenues ($7.5 million) as
compared to pro forma income from operations  amounting to $1.3 million or 9% of
pro forma net  revenues  ($14  million)  for the same period in prior year.  Pro
forma loss from operations  increased by $2.9 million from prior period which is
due to the  Administration  process  and the one time  start up and  integration
costs.

         During the  Administration  process,  the financial  performance of the
business  assets  acquired  by  Inyx  Pharma  was  adversely   affected  due  to
administration  costs,  the lack of  components  and  supplies,  and  subsequent
shipping delays to customers.

         Interest Expense

         Interest expense amounted to $159 thousand,  or approximately 3% of net
revenues  for the three  and six  month  periods  ended  June 30,  2003 and 2002
respectively.

         Pro forma interest expense for the six month period ended June 30, 2003
amounted to $588  thousand or 8% of net revenues as compared to $848 thousand or
6% of net revenue for the six month period ended June 30, 2002. Interest expense
for the six  month  period  ended  June 30,  2003  relates  to the  Inyx  Pharma
indebtedness  including  working capital  obtained to finance the acquisition of
Miza UK business assets.

         Depreciation and Amortization

         Depreciation   and   amortization   expenses   were  $128  thousand  or
approximately  3% of net revenue for the three month  period ended June 30, 2003
and $131  thousand or  approximately  3% of net revenue for the six month period
ended June 30, 2003.  The first quarter in the year includes  approximately  $10
thousand  relating to  depreciation  of livestock  which were part of the assets
sold to a third party by the Company.

         Pro forma  depreciation  expense amounted to $476 or 6% of net revenues
for the six month period ended June 30, 2003 as compared to $432  thousand or 3%
of net revenues for the six month period ended June 30, 2002.

         The Company  states the value of its  property  and  equipment at cost.
Depreciation is computed using the  straight-line  method based on the estimated
useful  lives of the  assets,  which range from 50 years for  buildings  to 3-10
years for equipment.

         Amortization  of trademarks and trade names,  and other  intangibles is
determined  utilizing the  straight-line  method based on the  estimated  useful
lives of the intangibles.



                                       18
<PAGE>

         Goodwill  is not  amortized  but will be  subject  to annual  review to
determine whether there is any impairment of the value ascribed to it.

         Net Income/Loss

         Net loss for the  three-months  and six-months  ended June 30, 2003 was
$1.5 million.

         Pro  forma  net loss  for the six  month  period  ended  June 30,  2003
amounted to $2.0  million as  compared to pro forma net income of $454  thousand
for the six month  ended June 30,  2002.  Pro forma net loss  increased  by $2.5
million  or  5.5%.  The  major  reason  for  the  change  is  attributed  to the
predecessor  company  operating  under  the  Administration  order in the  first
quarter of 2003. In addition the Company  incurred  start up costs in connection
with the acquisition regarding share exchange transaction and the phasing out of
the CFC product line.

         Although  the  business   assets  of  Miza  UK  were  acquired  out  of
Administration,  most of the customer base was retained and prior results may be
indicative   of  the  future   operations.   the  Company   expects  to  achieve
profitability  and have  positive  cash  flows  from the Miza UK  operations  it
acquired.  However,  there can be no assurance that the Company's forecasts will
be met.

EXPECTATIONS

         Although the Company's  subsidiary,  Inyx Pharma  acquired the business
assets of Miza UK out of Administration,  most of the customer base was retained
and  results  prior  to  the  Administration  period,  when  the  operation  was
profitable, may be indicative of the future operations.

         Certain contracts entered into during 2003 should enable the Company to
restore its revenues and  profitability  levels  previously  experienced  by the
predecessor  business  operation,  prior  to the  Administration  period.  These
contracts include a respiratory development and commercialization  contract with
a leading  pan-European  generic  pharmaceutical  manufacturer and a dermatology
development and commercialization contract with Stiefel Laboratories, Inc.

         Initially,  these agreements are expected to add approximately $800,000
to each of the  Company's  2003 and 2004  revenues and then  increasing  to $1.2
million in 2005.  Gross  profit is expected to exceed 30 percent as a percentage
of revenues.  Upon  commencement  of  commercial  manufacturing,  the  increased
manufacturing volume will also contribute to the Company's overall profitability
due  a  result  of  increased  capacity   utilization  and  subsequent  overhead
absorption.

LIQUIDITY AND CAPITAL RESOURCES

         The Company has financed its operations  primarily through revenue from
contract  manufacturing and product development  contracts,  stockholder equity,
credit   facilities,   and  financing  of  property,   equipment  and  inventory
acquisitions.  Additionally,  the Company has been  dependant  on funding of its
working capital from its major  stockholders  in the form of stockholder  loans.
However,  there is no binding obligation for these major stockholders to provide
additional  future  funding.  In  addition,  the Company is engaged in a private
placement of up to $3 million of common stock.


                                       19
<PAGE>

         The Company believes that existing credit facilities,  equity placement
and cash  generated  from  operations  are  sufficient  to finance  its  current
operations and working capital  requirements.  However,  as a result of the long
lead time required to order  specialized raw materials and components  necessary
for the manufacture of some of its customers' products,  the Company may require
additional working capital to support the purchase and storage of such supplies,
in order to meet those customers' delivery date requirements.  Additionally,  as
the Company expects to increase its capital expenditures over the next few years
as part of its  growth  strategy,  it may be  required  to raise  funds  through
additional borrowings or the issuance of additional debt or equity securities

         Also, in the event that Company makes significant  future  acquisitions
or changes its capital structure, it may also be required to raise funds through
additional  borrowings or the issuance of additional debt or equity  securities.
The Company is presently actively pursuing acquisitions that may require the use
of substantial capital resources. There are no present agreements or commitments
with respect to any such acquisitions.

Analysis of Cash Flows
----------------------

         Three and six month period ended June 30, 2003

         The net cash used in operating  activities  for the three months period
ended June 30, 2003 was $3.7 million.  The net cash used in operating activities
includes a net loss from  continuing  operations  of $1.5  million  adjusted  by
non-cash charges which includes  depreciation and amortization of $128 thousand,
deferred income taxes of $299, and issuance of stock as compensation of services
amounting to $799. Net change in non cash operating working capital increased by
$2.9 million,  mostly attributed to the start up of operations under Inyx Pharma
including an accounts receivables increase of $3 million as compared to the same
period in the prior year. Inventory prepaids and other assets and deferred taxes
also increased by $845  thousand,  $1.1 million and $299 thousand as compared to
same period in prior year.

         The net cash  provided by  financing  activities  for the three and six
month  period ended June 30, 2003 was  approximately  $9.8  million.  During the
three and six month  period the long term debt issued  amounting to $3.2 million
and proceeds from issuance of  promissory  notes  amounting to $4.2 million were
used  for  acquisition  of the  business  assets  of Miza UK  including  working
capital.  The  remainder  of the cash  provided  from the  proceeds of a line of
credit  amounting to $2.3 million was used to support  operations.  Stockholders
provided  $109  thousand and $50 thousand in advances in the three month and six
month periods ended June 30, 2003 respectively.

         The net cash  used by  investing  activities  during  the three and six
month  period  ended June 30,  2003 was $6.1  million.  During the three and six
month period ended June 30, 2003 $5,280 was used for acquisition of fixed assets
and $841 thousand related to out of pocket direct costs of acquisition.

External Sources of Liquidity
-----------------------------

         The  Company's  cash needs for the  remainder of 2003 will be primarily
related  to  capital  expenditures,   additional  working  capital  to  purchase
materials and  components to meet  increasing  production  requirements  and the
necessary working capital to meet increasing corporate development costs.



                                       20
<PAGE>

         It is  anticipated  that the  Company  will  spend  approximately  $2.5
million  in  capital  expenditures  in 2003  for its Inyx  Pharma  manufacturing
operation.  As a result of renewed  customer  contracts,  new customer  purchase
orders,  increasing corporate  development and marketing costs, the Company will
require  an  additional  $2.5  million in working  capital.  Approximately  $1.5
million of working  capital  will be  utilized  to purchase  raw  materials  and
components  in advance  to  complete  customers'  production  requirements.  The
remainder of the working  capital is required to meet the  Company's  increasing
corporate  costs as it expands its business and corporate  development  programs
including  investor  relation  expenses,  acquisition  due  diligence  costs and
consulting fees.

         The  Company  may be  required  to raise the  required  funds for these
capital   expenditures  and  working  capital  requirements  through  additional
borrowings or through the issuance of additional debt or equity securities.

Item 3. Controls and Procedures

         The  Company  carried out an  evaluation  of the  effectiveness  of the
design and  operation  of its  disclosure  controls and  procedures  pursuant to
Exchange Act Rule 13a-14.  This  evaluation was done under the  supervision  and
with the  participation  of the Company's  Chairman,  and its Vice  President of
Finance.  Based  upon  that  evaluation,   they  concluded  that  the  Company's
disclosure  controls and  procedures  are effective in gathering,  analyzing and
disclosing  information needed to satisfy the Company's  disclosure  obligations
under the Exchange Act.





















                                       21
<PAGE>


                          PART II -- OTHER INFORMATION

Item 2.  Changes in Securities

         The following  equity  securities were issued by Registrant  during the
second quarter of 2003.

         On April 22, 2003, the Company  announced that it had agreed to acquire
all of the issued and outstanding securities of Inyx Pharma Limited, a specialty
pharmaceutical  company  incorporated under the laws of England and Wales ("Inyx
Pharma"). Pursuant to that announcement,  on April 17, 2003, the Company entered
into an  Agreement  with  five  parties  in which  the  Company  agreed to issue
2,450,000 of shares of  restricted  common  stock as a fee to these  parties for
their role in facilitating the transaction with Inyx Pharma.

         On April 21, 2003,  the Company  also entered into a two year  Business
Advisory and  Financial  Consulting  Services  Agreement  with a  consultant  to
provide advice and counsel regarding the Company's  strategic business plans. As
consideration for this Consulting Agreement, the Company issued 1,500,000 shares
of restricted  securities to the Consultant.  The Company  subsequently filed an
S-8 registration statement to register those securities on June 26, 2003.

         On April 28,  2003,  the  Company  concluded  its  acquisition  of Inyx
Pharma.  The  transaction  consisted  of an exchange of 100% of the  outstanding
common stock of Inyx Pharma, for 16 million shares of restricted common stock of
the  Company  (the  "Exchange"),  representing  approximately  64% of the shares
outstanding after the exchange, as a result of which Inyx Pharma became a wholly
owned  subsidiary  of  the  Company.   Inyx  Pharma  focuses  its  expertise  on
development-led  manufacturing  in the sterile  pharmaceutical,  finished-dosage
form,  outsourcing sector. It specializes in niche products and technologies for
the treatment of respiratory,  allergy, dermatological,  and topical conditions.
Inyx  Pharma's  client base is  comprised of  blue-chip  ethical  pharmaceutical
companies, branded generic firms and biotechnology groups.

         On May 1, 2003 the Company  adopted a Stock  Option Plan that  provides
for the granting of incentive  stock options and non qualified stock options for
the benefit of employees officers and directors. The total number of shares that
may be issued under the plan amounts to 5,000,000.  The exercise price per share
must be at least equal to the fair market price at the time of grant.

         On June 26, 2003 The  Company  entered  into a three  month  Consulting
Agreement with National Financial  Communications Corp. for public relations and
communications  services.  As part of the  Consideration  for this agreement the
Company issued  warrants to purchase a maximum of 300,000 whole shares of common
stock of the  Company  at prices  ranging  from  $1.10 to $3.10 per  share.  The
warrants expire in September 2006.

         All such securities were issued in private placement transaction exempt
from registration under Section 4(2) of the Securities Act of 1933, Regulation D
or Regulation S.

Item 4.  Submission of Matters to a Vote of Security Holders

         Effective  May 1,  2003,  the  holders of  13,150,000  shares of common
stock, representing 52.71 % of shares outstanding, executed a consent in writing
amending and  restating the Articles of  Incorporation,  adopting the 2003 Stock
Option Plan,  establishing  the number of  directors at six, and electing  three
directors  consisting  of Jack  Kachkar,  Ron  Hodgson  and Steve  Handley.  Two
additional  directors,  Douglas  Brown and Colin  Hunter  have been added by the
Board to fill vacancies.

Item 5. Other Information.

         On July 1,  2003  the  Company  entered  into a two year  Business  and
Corporate  Development  Advisory Consulting Services Agreement (the "Agreement")
with a  consultant  to  provide  advice  and  council  regarding  the  Company's
strategic   business  and  development   plans  and  other   consulting   needs.
Consideration for this Agreement amounts to approximately  $170,000 over the two
year term.

Item 6.  Exhibits and Reports on Form 8-K.

         (a)      Exhibits

                  10.14    Consulting Agreement dated June 1, 2003 with National
                           Financial Communications Corp.

                  10.15    Stock  Purchase  Warrant  dated  June 26,  2003  with
                           National Financial Communications Corp.

                  10.16    Stock Purchase  Warrant dated June 26, 2003 with Gary
                           Geraci.

                  10.17    Business  Consulting Services Agreement dated July 1,
                           2003 with Marc Couturier.

                  31.1     Certification  of Jack Kachkar  under  Section 302 of
                           the Sarbanes-Oxley Act of 2002 is furnished hereby.

                  31.2     Certification of Rima Goldshmidt under Section 302 of
                           the Sarbanes-Oxley Act of 2002 is provided hereby.

                  32.1     Certification  of Jack Kachkar  under  Section 906 of
                           the Sarbanes-Oxley Act of 2002 is furnished hereby.

                  32.2     Certification of Rima Goldshmidt under Section 906 of
                           the Sarbanes-Oxley Act of 2002 is provided hereby.

         (b)      Reports on Form 8-K.

         On February 19, 2003, Registrant filed a Form 8K reporting under item 5
that a press release was issued on February 19, 2003,  announcing a five for one
forward split of the Company's common stock.



                                       22
<PAGE>

         On April 2, 2003 Registrant filed a Form 8K reporting a change of
control of the Registrant under item 1 and a Change in Registrant's Certifying
Accountant under item 4.

         On May 13, 2003, Registrant filed a Form 8K describing in Items 1 and 2
a material acquisition and change of control of Registrant.

         On June 24, 2003, Registrant filed a Form 8K/A supplementing the Form
8K filed on May 13, 2003, with financial statements and a Management's Decision
and Analysis or Plan of Operations.



























                                       23
<PAGE>


                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.

Date:    August 19, 2003

INYX, INC.


By: /s/ Rima Goldshmidt
   ----------------------
   Rima Goldshmidt,
   Vice President Finance






























                                       24